CY1123906T1 - Αναστολεις απομεθυλασης ιστονης - Google Patents
Αναστολεις απομεθυλασης ιστονηςInfo
- Publication number
- CY1123906T1 CY1123906T1 CY20211100169T CY211100169T CY1123906T1 CY 1123906 T1 CY1123906 T1 CY 1123906T1 CY 20211100169 T CY20211100169 T CY 20211100169T CY 211100169 T CY211100169 T CY 211100169T CY 1123906 T1 CY1123906 T1 CY 1123906T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cancer
- compounds
- compositions
- useful
- treatment
- Prior art date
Links
- 108010033040 Histones Proteins 0.000 title 1
- 230000017858 demethylation Effects 0.000 title 1
- 238000010520 demethylation reaction Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000008157 Histone Demethylases Human genes 0.000 abstract 1
- 108010074870 Histone Demethylases Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- -1 pyridine derivative compounds Chemical class 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462017201P | 2014-06-25 | 2014-06-25 | |
| PCT/US2015/037812 WO2015200709A1 (en) | 2014-06-25 | 2015-06-25 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123906T1 true CY1123906T1 (el) | 2022-05-27 |
Family
ID=54929774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100169T CY1123906T1 (el) | 2014-06-25 | 2021-03-01 | Αναστολεις απομεθυλασης ιστονης |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10385047B2 (enExample) |
| EP (3) | EP3738960A1 (enExample) |
| JP (1) | JP6521535B2 (enExample) |
| KR (1) | KR102591897B1 (enExample) |
| CN (2) | CN106660982B (enExample) |
| AR (1) | AR100997A1 (enExample) |
| AU (1) | AU2015279719B2 (enExample) |
| BR (1) | BR112016030367A2 (enExample) |
| CA (1) | CA2953437C (enExample) |
| CL (1) | CL2016003301A1 (enExample) |
| CO (1) | CO2017000359A2 (enExample) |
| CY (1) | CY1123906T1 (enExample) |
| DK (1) | DK3160952T3 (enExample) |
| EA (1) | EA031200B1 (enExample) |
| EC (1) | ECSP17004931A (enExample) |
| ES (1) | ES2862648T3 (enExample) |
| HR (1) | HRP20210299T1 (enExample) |
| HU (1) | HUE053876T2 (enExample) |
| IL (1) | IL249629A0 (enExample) |
| LT (1) | LT3160952T (enExample) |
| MX (1) | MX375219B (enExample) |
| NZ (1) | NZ728120A (enExample) |
| PL (1) | PL3160952T3 (enExample) |
| PT (1) | PT3160952T (enExample) |
| SA (1) | SA516380585B1 (enExample) |
| SG (1) | SG11201610813TA (enExample) |
| SI (1) | SI3160952T1 (enExample) |
| TW (2) | TWI758004B (enExample) |
| WO (1) | WO2015200709A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2895808A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| CN106660982B (zh) | 2014-06-25 | 2020-09-08 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| SG11201702147TA (en) | 2014-09-17 | 2017-04-27 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3397617A4 (en) * | 2015-12-28 | 2019-05-22 | Celgene Quanticel Research, Inc. | HISTONDEMETHYLASEINHIBITOREN |
| WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| ES2991090T3 (es) | 2017-03-30 | 2024-12-02 | Univ Freiburg Albert Ludwigs | Inhibidores de KDM4 |
| CN109825551B (zh) * | 2019-02-21 | 2022-08-02 | 深圳大学 | 一种评价组蛋白赖氨酸去甲基转移酶活性的方法 |
| CN111679072B (zh) * | 2020-06-15 | 2022-04-29 | 温州医科大学 | Kdm6b蛋白在乳腺癌预后评估试剂盒、诊断试剂盒中的应用 |
| US20250025451A1 (en) * | 2021-04-09 | 2025-01-23 | Celgene Corporation | Treatment of cancer with kdm4 inhibitors |
| AU2022331536A1 (en) * | 2021-08-18 | 2024-02-22 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
| WO2023122221A1 (en) * | 2021-12-23 | 2023-06-29 | Tachyon Therapeutics, Inc. | Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid |
| AR129578A1 (es) | 2022-06-10 | 2024-09-11 | Forward Therapeutics Inc | MODULADORES DE LA ACTIVIDAD DE TNF-a |
| US20250241905A1 (en) * | 2022-06-23 | 2025-07-31 | The Cleveland Clinic Foundation | 3-beta-hsd1 inhibitors and compositions and uses thereof |
| JP2025532101A (ja) * | 2022-09-21 | 2025-09-29 | セルジーン コーポレーション | ３－（｛［（４ｒ）－７－｛メチル［４－（プロパン－２－イル）フェニル］アミノ｝－３，４－ジヒドロ－２ｈ－１－ベンゾピラン－４－イル］メチル｝アミノ）ピリジン－４－カルボン酸のｌ－リジン塩、ヒストンデメチラーゼ阻害剤 |
| CN115974647B (zh) * | 2022-12-05 | 2024-09-03 | 江苏宏邦化工科技有限公司 | 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法 |
| IL327679A (en) * | 2023-10-16 | 2026-06-01 | Cleveland Clinic Found | 3?hsd1 inhibitors and compositions and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2465978C (en) * | 2001-09-14 | 2015-04-07 | Soon Hyung Woo | Inhibitors of histone deacetylase |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004039876A1 (de) | 2004-06-23 | 2006-01-26 | Lanxess Deutschland Gmbh | Herstellung von fluorierten 1,3-Benzodioxanen |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| CA2648804C (en) * | 2006-04-07 | 2014-05-27 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| US7898712B2 (en) | 2008-06-27 | 2011-03-01 | Lockheed Martin Corporation | Risley integrated steering module |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| WO2013143597A1 (en) | 2012-03-29 | 2013-10-03 | Glaxo Group Limited | Demethylase enzymes inhibitors |
| US20140162266A1 (en) | 2012-12-05 | 2014-06-12 | Bio-Rad Laboratories, Inc. | Methods for polymerase chain reaction copy number variation assays |
| US8987461B2 (en) * | 2012-12-06 | 2015-03-24 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| SI2934145T1 (en) * | 2012-12-19 | 2018-03-30 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CA2895808A1 (en) * | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| CN106660982B (zh) | 2014-06-25 | 2020-09-08 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| ES2991090T3 (es) * | 2017-03-30 | 2024-12-02 | Univ Freiburg Albert Ludwigs | Inhibidores de KDM4 |
-
2015
- 2015-06-25 CN CN201580045921.2A patent/CN106660982B/zh active Active
- 2015-06-25 US US15/321,702 patent/US10385047B2/en active Active
- 2015-06-25 CN CN202010813617.0A patent/CN111909083B/zh active Active
- 2015-06-25 KR KR1020177002223A patent/KR102591897B1/ko active Active
- 2015-06-25 EA EA201692483A patent/EA031200B1/ru unknown
- 2015-06-25 LT LTEP15811523.8T patent/LT3160952T/lt unknown
- 2015-06-25 WO PCT/US2015/037812 patent/WO2015200709A1/en not_active Ceased
- 2015-06-25 CA CA2953437A patent/CA2953437C/en active Active
- 2015-06-25 DK DK15811523.8T patent/DK3160952T3/da active
- 2015-06-25 HR HRP20210299TT patent/HRP20210299T1/hr unknown
- 2015-06-25 MX MX2016017407A patent/MX375219B/es active IP Right Grant
- 2015-06-25 JP JP2016574454A patent/JP6521535B2/ja active Active
- 2015-06-25 EP EP20184107.9A patent/EP3738960A1/en not_active Withdrawn
- 2015-06-25 BR BR112016030367A patent/BR112016030367A2/pt not_active Application Discontinuation
- 2015-06-25 PT PT158115238T patent/PT3160952T/pt unknown
- 2015-06-25 TW TW109143458A patent/TWI758004B/zh active
- 2015-06-25 EP EP20184106.1A patent/EP3741749A1/en active Pending
- 2015-06-25 ES ES15811523T patent/ES2862648T3/es active Active
- 2015-06-25 TW TW104120633A patent/TWI715533B/zh active
- 2015-06-25 SG SG11201610813TA patent/SG11201610813TA/en unknown
- 2015-06-25 HU HUE15811523A patent/HUE053876T2/hu unknown
- 2015-06-25 NZ NZ728120A patent/NZ728120A/en unknown
- 2015-06-25 US US14/751,007 patent/US9242968B2/en active Active
- 2015-06-25 EP EP15811523.8A patent/EP3160952B1/en active Active
- 2015-06-25 AU AU2015279719A patent/AU2015279719B2/en active Active
- 2015-06-25 AR ARP150102042A patent/AR100997A1/es not_active Application Discontinuation
- 2015-06-25 SI SI201531524T patent/SI3160952T1/sl unknown
- 2015-06-25 PL PL15811523T patent/PL3160952T3/pl unknown
- 2015-12-09 US US14/963,754 patent/US9447046B2/en active Active
-
2016
- 2016-07-26 US US15/220,118 patent/US9586902B2/en active Active
- 2016-12-18 IL IL249629A patent/IL249629A0/en unknown
- 2016-12-22 CL CL2016003301A patent/CL2016003301A1/es unknown
- 2016-12-22 SA SA516380585A patent/SA516380585B1/ar unknown
-
2017
- 2017-01-09 US US15/402,100 patent/US9815828B2/en active Active
- 2017-01-16 CO CONC2017/0000359A patent/CO2017000359A2/es unknown
- 2017-01-24 EC ECIEPI20174931A patent/ECSP17004931A/es unknown
- 2017-10-24 US US15/792,570 patent/US9994561B2/en active Active
-
2018
- 2018-05-04 US US15/971,749 patent/US10106534B2/en active Active
-
2021
- 2021-03-01 CY CY20211100169T patent/CY1123906T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1125855T1 (el) | Αναστολεις της ειδικης για τη λυσινη απομεθυλασης-1 | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CY1119476T1 (el) | Αναστολεις της απομεθυλασης ιστονης | |
| CY1125245T1 (el) | Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| MX375219B (es) | Inhibidores de histona demetilasa. | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| IL268676A (en) | Inhibition of smarca2 for treatment of cancer | |
| MX391865B (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| ECSP17020172A (es) | Inhibidores de histona desmetilasa | |
| ECSP17023551A (es) | Inhibidores de histona desmetilasa | |
| CO2017003445A2 (es) | Inhibidores de la histona desmetilasa | |
| EA201992022A1 (ru) | Терапевтическая рнк | |
| IL268897A (en) | Medicament for malignant tumor treatment |